Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Dong Xiao, Ph.D., University of Pittsburgh: Based on the report of an inquiry conducted by the University of Pittsburgh (UP), additional analysis conducted by ORI in its oversight review, and an admission by the Respondent that he had "intentionally fabricated data contained in a paper entitled `Guggulsterone inhibits prostate cancer growth via inactivation of Akt regulated by ATP citrate signaling,' specifically Figure 6G," ORI found that Dr. Dong Xiao, former Research Assistant Professor, Department of Urology, UP, engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grant R01 CA157477. ORI found that Respondent engaged in research misconduct by reporting falsified data in Figures 1, 4, 5, S2, and S3 in the following paper published online: <bullet> Gao, Y., Zeng, Y., Tian, J., Kslam, M.S., Jiang, G.,
A formal finding of research misconduct under 42 CFR part 93 (HHS) or equivalent agency policy. The respondent was found to have engaged in fabrication, falsification, or plagiarism of research data. The federal grant funds involved are typically identified in the FR notice, along with the administrative actions (debarment, supervised research, manuscript correction or retraction requirements).